Share

April 2016; 3 (2) Clinical/Scientific NotesOpen Access

Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab

Markus C. Kowarik, Muna Hoshi, Bernhard Hemmer, Achim Berthele
First published February 10, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000208
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
695

Share

Article Information

vol. 3 no. 2 e208
DOI: 
https://doi.org/10.1212/NXI.0000000000000208
PubMed: 
26913290
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received October 19, 2015
  • Accepted in final form December 23, 2015
  • First Published February 10, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Markus C. Kowarik, MD,
    2. Muna Hoshi, MD,
    3. Bernhard Hemmer, MD and
    4. Achim Berthele, MD
  1. Markus C. Kowarik, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. funding for travel from Merck-Serono ca. 400 Euro and Bayer Health Care ca. 300 Euro, Novartis 600 Euro.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Grant from Novartis.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Funding for other research projects was received from Novartis (not related to this study).

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Muna Hoshi, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Funding for travel from Bayer Health Care, Biogen Idec, Merck Serono

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Bernhard Hemmer, MD and
    4. Scientific Advisory Boards:

    1. Advisory board member for trials conducted by Bayer, BiogenIdec, Roche, Novartis, MerckSerono, Chugai, GSK, Genentech.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Sponsoring was received from Bayer, BiogenIdec, Roche, Novartis, MerckSerono for travelling and talks

    Editorial Boards:

    1. Archives of Neurologie, Experimental Neurology, MS Journal

    Patents:

    1. (1) Anti-KIR4.1 antibody testing in MS (2) Genetic factors influencing the development of NABs

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Gerson Lehrman Group

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from Bayer, BiogenIdec, Roche, Novartis, MerckSerono, Metanomics, Chugai Pharmaceuticals.

    Research Support, Government Entities:

    1. Deutsche Forschungsgemeinschaft, Bundesministerium f?r Bildung und Forschung, European Community.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Competence Network for Multiple Sclerosis Synergy Excellence Cluster German Research Foundation Bundesministerium f?r Bildung und Forschung

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Achim Berthele, MD
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I received funding for travel and speaker honoraria from Biogen Idec, Merck Serono, Novartis, Teva and Bayer Healthcare.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research grant from Bayer Healthcare (Commercial entity)

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From Klinikum rechts der Isar der Technischen Universität München (M.C.K., M.H., B.H., A.B.); and Munich Cluster for Systems Neurology (SyNergy) (B.H.), Germany.
  1. Correspondence to Dr. Kowarik: kowarik{at}lrz.tum.de
View Full Text

Article usage

Article usage: February 2016 to August 2023

AbstractFullPdfSource
Feb 20161957124Highwire
Feb 2016062pmc
Mar 201612219516Highwire
Mar 201603813pmc
Apr 20161364031Highwire
Apr 20160187pmc
May 20163127312Highwire
May 20160124pmc
Jun 2016351210Highwire
Jun 20160115pmc
Jul 2016191113Highwire
Jul 20160104pmc
Aug 20162478Highwire
Aug 2016051pmc
Sep 20161653Highwire
Sep 2016081pmc
Oct 201621124Highwire
Oct 2016032pmc
Nov 20165356Highwire
Nov 20160121pmc
Dec 20161031Highwire
Dec 2016063pmc
Jan 201715236Highwire
Jan 20170151pmc
Feb 2017422Highwire
Feb 2017086pmc
Mar 201713582Highwire
Mar 20170112pmc
Apr 20178490Highwire
Apr 2017247pmc
May 2017462Highwire
May 2017146pmc
Jun 2017744Highwire
Jun 201741010pmc
Jul 2017300Highwire
Jul 2017076pmc
Aug 2017541Highwire
Aug 2017044pmc
Sep 2017800Highwire
Sep 2017122pmc
Oct 2017811Highwire
Oct 2017066pmc
Nov 2017702Highwire
Nov 2017264pmc
Dec 2017032Highwire
Jan 2018151Highwire
Feb 20180102Highwire
Mar 2018063Highwire
Apr 201802311Highwire
Apr 2018178pmc
May 20180143Highwire
Jun 20182102Highwire
Jun 2018055pmc
Jul 2018073Highwire
Aug 20182132Highwire
Aug 20182911pmc
Sep 20181112Highwire
Oct 20181113Highwire
Nov 2018080Highwire
Dec 2018090Highwire
Jan 2019160Highwire
Feb 2019091Highwire
Mar 2019154Highwire
Apr 2019477Highwire
May 20195146Highwire
Jun 20192287Highwire
Jul 201911112Highwire
Aug 201921611Highwire
Sep 20191113Highwire
Oct 20190602Highwire
Nov 20190223Highwire
Dec 20190455Highwire
Jan 2020073Highwire
Feb 2020282Highwire
Mar 2020058Highwire
Apr 20201914Highwire
May 2020185Highwire
Jun 20201129Highwire
Jul 2020095Highwire
Aug 2020132Highwire
Sep 202021020Highwire
Oct 2020176Highwire
Nov 2020166Highwire
Dec 20201105Highwire
Jan 20212139Highwire
Feb 2021055Highwire
Mar 2021047Highwire
Apr 2021053Highwire
May 20211153Highwire
Jun 20212103Highwire
Jul 202121414Highwire
Aug 20212153Highwire
Sep 20210211Highwire
Oct 202101423Highwire
Nov 202111117Highwire
Dec 20210143Highwire
Jan 2022073Highwire
Feb 20221124Highwire
Mar 202201210Highwire
Apr 2022085Highwire
May 2022186Highwire
Jun 2022095Highwire
Jul 2022084Highwire
Aug 20220176Highwire
Sep 20221219Highwire
Oct 202212612Highwire
Nov 202204921Highwire
Dec 20220227Highwire
Jan 20230217Highwire
Feb 202302112Highwire
Mar 2023267Highwire
Apr 20230106Highwire
May 20232117Highwire
Jun 2023152Highwire
Jul 2023387Highwire
Aug 2023055Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles